Cristina Sarasqueta-rekin lankidetzan egindako argitalpenak (10)

2017

  1. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

    United European Gastroenterology Journal, Vol. 5, Núm. 2, pp. 255-260

2016

  1. Effect of pravastatin on the survival of patients with advanced gastric cancer

    Oncotarget, Vol. 7, Núm. 4, pp. 4379-4384

2014

  1. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    Clinical Gastroenterology and Hepatology, Vol. 12, Núm. 10, pp. 1708-1716.e4

2013

  1. Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer

    PLoS ONE, Vol. 8, Núm. 1

2010

  1. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method

    World Journal of Gastroenterology, Vol. 16, Núm. 12, pp. 1495-1499

  2. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  3. Niveles plasmóticos de la vitamina B12 y ácido fólicoenpacientes con hepatopatía crónica

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 4, pp. 280-287

2009

  1. Características clinicopatológicas y supervivencia de los pacientes con cáncer de esófago. Resultados de 200 casos consecutivos

    Medicina Clinica, Vol. 133, Núm. 18, pp. 689-693

2008

  1. Resveratrol inhibits nonalcoholic fatty liver disease in rats

    BMC Gastroenterology, Vol. 8

2006

  1. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice

    BMC Gastroenterology, Vol. 6